

AGATHA PHARMACEUTICALS

Board Candidate Backgrounds

Company shares breakdown:

\$81.44 per share

Agatha: 25% voting shares

Balwani: 12% voting shares

Harris et al: 9% voting shares

Medici Hospital Group: 8% voting shares

Romney Capital: 6% voting shares

Weber Health investors: 3% voting shares

Other investors: 37% voting shares

Christopher Agatha is stepping down from his Board position in a few days. Due to the vacancy, we are soliciting applications for the Board. All candidates must be current shareholders, and will be voted on by the rest of the shareholders for the position.

Elizabeth Balwani

Balwani is a candidate for the Board of Directors. As an original co-founder of the company back in 1970 and the current COO, Balwani has overseen much of the business operations over the past 40 years. She is an aggressive, ambitious leader; she is known to interrupt people while they are speaking to more quickly get to the point, and is effective at making deals.

She is planning on stepping down from her position as COO to transition into the Board role. Her platform as a candidate has a few major points:

1. She views her direct company experience as an asset
2. She argues that the company should aggressively transition to its new line of biomechanical engineering products, and that she will help the company find partnerships with major medical groups

3. For its existing suite of pharmaceutical drugs, she argues that the company should seek to change its pricing, and pursue higher profit margins particularly before the intellectual property expires

Nora Harris

Harris is a candidate for the Board of Directors. Despite her youth, Harris has had a diverse career: she has been an Agatha Fellow, was a popular stand-up comedian with her own Netflix special, and is now an impact investor.

Harris is rambunctious and regularly challenges norms: for example, she is known for cutting her hair short and wearing a suit, to challenge notions around masculinity and femininity.

As an impact investor, Harris' platform is as follows:

1. She believes the company needs a fresh perspective
2. She thinks the company should be more transparent in its drug pricing, and clearly articulate for the public how prices are set (e.g. cost of manufacturing, total cost of research, profit margins, etc.)
3. She wants to make the company carbon-neutral by 2030.
4. She wants to re-examine the product design for many of the biomechanical products, namely how its data may impact patient privacy

Dear Diary,

Wow -- tomorrow's the big day. Not that I really care for Agatha himself (and this is honestly an understatement, the man can die for all I care), but so many of the attendees are going to be important for me.

Everyone's got the **background** for the company at this point -- Weber Health is one of the fastest-growing startups in the country, after all. People told me transitioning from a supermodel career, especially from an underwear and body-focused company like Cornea, is difficult. But I've been pretty good at leveraging all that fame and my business education from the Fellowship (maybe Agatha was good for something after all?) into a new line of health-related products.

Specifically, people have really liked my health supplements. There's a wide variety my pharmacists have created, from weight loss to hair regrowth. And all of it, FDA approved! Looks like my ambition is paying off.

Although -- and this is just a **secret** between you and me, diary -- obviously that approval wasn't that legit. I know someone at the FDA who has some influence, and he got it through the regulatory process for me a little faster and maybe a little looser than what they might do for other products. But hey, a little supplement never hurt anyone. And it's certainly helping me make money.

"Anyway, even though it's taken off, I still need more capital to keep it growing. I would've thought Agatha would be the one to do that, since I'm one of his Fellows and all, but when I emailed him last week, I got the most dismissive response I have ever heard. It was even worse than all those asshole Series A investors! Like, sure, is the product actually legit? No. But Agatha doesn't know that. And I don't need his fucking arrogance. And worse yet, Agatha even laughed at the fact that I have a modeling background -- he asked how I would even know how to create an actual supplement! I

can't stand that -- I've met so many of them, the rich people who hear that I was on magazine covers in underwear, and smirk to themselves while backhandedly complimenting me. They'll see, when I'm richer and more successful than all of those fuckers."

Yeah, I'm ambitious. And I'm not going to tolerate anyone standing in my way.

But anyway, I'm getting ahead of myself. Still have to charm people at the event, even if Agatha, that old fart, isn't going to help:

1. Carter Desmond: I'm trying to secure an Agatha Foundation sponsorship of my health supplements for their charity work in Africa
2. Peter Dalio: I'm trying to secure increased investment from Romney Capital
3. Harold Beech: haven't talked to him yet, but a lot of the initial feedback I've gotten has been about needing to build more credibility for my product. I would be willing to do anything to get his endorsement. I've heard, though, that his wife is super stingy.... really wish she were out of the picture.
4. Robert Godfried: I also heard from him recently -- didn't really know who he was, but evidently he's a tennis player? He was reaching out about a potential brand sponsorship -- could be nice to have an athlete on board too. Would like to learn more about him first though.

Lastly, I've also heard that there's a board race at Agatha Pharmaceuticals, now that Agatha is leaving the company. I've invested in the company, so I get a vote -- but it will be interesting to see what the dynamics at play are, and what everyone else is doing first. Maybe I'll be able to use that as leverage somewhere else?

Anyway -- I'm off to bed. Will need to be well rested for the dinner.